Industry: Healthcare | Publish Date: 28-Nov-2024 | No of Pages: 314 | No. of Tables: 169 | No. of Figures: 139 | Format: PDF | Report Code : HC367
At an estimated value of over USD 1.92 billion in 2023, the Global Metagenomics Market is predicted to thrive at a CAGR of 13.2% and valued at over USD 4.57 billion over the forecast year 2024-2030.
Metagenomics encompasses various studies that use bioinformatic tools as well as sequencing technologies to attain valuable understanding on the varieties in the microbial community and microbes’ interaction in a community. These studies are making advancements across environmental & clinical microbiology, despite considerable barriers such as difficulty to enable a microbial culture, which is a method of multiplying microbial organisms. The technologies in metagenomics have allowed enhanced understanding of the microbial ecosystem along with the role of microbiology in the geochemical cycles. This has led to the understanding of the enormous microbial diversity for researchers, fueling the global market growth.
The global metagenomics market is majorly driven by factors such as rise in investments across the development of bioinformatics platforms to support microbiome profiling & metagenomics and increasing applications of metagenomics across various fields such as identification of novel biocatalysts, personalized medicine, discovery of new antibiotics, and bioremediation. Also, funding as well as initiatives from private bodies and government for large-scale sequencing projects is anticipated to promote the growth of metagenomics market. However, lack of awareness about metagenomics is expected to hamper the market growth during the forecast period. Contradictorily, the adoption of cloud computing for data management in the field of metagenomics is expected to create opportunities, which will further propel the metagenomics market growth.
The global metagenomics market share is segmented on the basis of product, technology, application, and geography. On the basis of product type, the market is categorized into instrument & software and consumable. On the basis of technology, the market is segmented into bioinformatics and sequencing. On the basis of application, the market is segmented into infectious disease diagnosis, environmental remediation, biotechnology, gut microbe characterization, biofuel, and agriculture. Geographic fragmentation and analysis of each segment includes regions comprising North America, Europe, Asia Pacific and RoW.
In terms of geography, North America held major share of the market in 2019. This is due to the growing adoption of DNA sequencing across metagenomic applications in the region. In addition, surge in the implementation of novel sequencing technologies across the region has significantly contributed to its dominance. However, Asia pacific is expected to grow rapidly with increasing market size due to the significant patient pool as well as the rapidly evolving healthcare infrastructure in countries such as China, India, and Japan.
Maximum growth opportunities make the metagenomics market highly competitive. Some of the major players in the market are Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Enterome SA, Illumina, Inc., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies Ltd., PerkinElmer, Inc., Swift Biosciences, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc., and many more. A number of developmental strategies have been adopted by companies in the past few years. For instance, in February 2019, Agilent Technologies, Inc. launched a new next-generation sequencing (NGS) library preparation system which is designed for easily running the complex DNA sequencing assays. This fully automated Magnis NGS Prep System encompasses reagents and protocols that enables an easy examination of multiple genes & complex genetic aberrations from genomic DNA, such as degraded samples including formalin-fixed paraffin embedded (FFPE).
The metagenomics market report provides the quantitative analysis of the current market and estimations through 2024-2030 that assists in identifying the prevailing market opportunities to capitalize on.
The study comprises an extensive analysis of the metagenomics market trend including the current and future trends for depicting the prevalent investment pockets in the market
The information related to key drivers, restraints and opportunities and their impact on the metagenomics market is provided in the report.
The market share of the players in the global metagenomics market along with their competitive analysis.
Value chain analysis in the market study provides a clear picture of the stakeholders’ roles.
Instrument & Software
Consumable
Sequencing
Bioinformatics
Infectious Disease Diagnosis
Environmental Remediation
Biotechnology
Gut Microbe Characterization
Biofuel
Agriculture
North America
U.S.
Canada
Mexico
Europe
UK
Germany
Italy
Spain
Netherlands
Rest of Europe
Asia-Pacific
China
India
Japan
South Korea
Australia
Taiwan
Vietnam
Rest of Asia-Pacific
Rest of World
Latin America
Middle East
Africa
Agilent Technologies, Inc.
F. Hoffmann-La Roche Ltd.
Enterome SA
Illumina, Inc.
Pacific Biosciences of California, Inc.
Oxford Nanopore Technologies Ltd.
PerkinElmer, Inc.
Swift Biosciences, Inc.
Qiagen N.V.
Thermo Fisher Scientific, Inc.
REPORT SCOPE AND SEGMENTATION:
Parameters |
Details |
Analysis Period |
2023–2030 |
Base Year Considered |
2023 |
Forecast Period |
2024–2030 |
Market Size Estimation |
Billion (USD) |
Market Segmentation |
By Product (Instrument & Software, Consumable) By Technology (Sequencing, Bioinformatics) By Application (Infectious Disease Diagnosis, Environmental Remediation, Biotechnology, Gut Microbe Characterization, Biofuel, Agriculture) |
Geographical Segmentation |
North America (U.S., Canada, Mexico) Europe (UK, Germany, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, Taiwan, South Korea, Vietnam, Rest of APAC), Rest of the World (Latin America, Middle East, Africa) |
Companies Profiled |
Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Enterome SA, Illumina, Inc., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies Ltd., PerkinElmer, Inc., Swift Biosciences, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc. |